US-based Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK) has announced that China’s National Medical Products Administration (NMPA) has approved an extended indication for its antifungal agent Noxafil (posaconazole) to include pediatric patients in the prevention and treatment of fungal infections. This approval covers two dosage forms: enteric-coated tablets and injection, expanding the drug’s accessibility to a younger demographic in China.
Noxafil’s Next-Generation Antifungal Profile
Noxafil is a next-generation triazole antifungal drug that is now available in three dosage forms: oral suspension, enteric-coated tablets, and injection. The posaconazole oral suspension has been approved for marketing in China for the prevention of invasive aspergillus and candida infections, as well as the treatment of oropharyngeal candidiasis. The enteric-coated tablets and injection forms are approved for the prevention of invasive aspergillus and candida infections and the treatment of invasive aspergillosis.
Enhancing Pediatric Care with Broadened Indication
The NMPA’s approval of Noxafil for pediatric patients marks a significant step forward in enhancing the treatment options available for young patients suffering from fungal infections. By expanding the indication to include children, MSD’s Noxafil now offers a comprehensive solution for both prevention and treatment of invasive fungal infections across various patient populations in China.-Fineline Info & Tech
Leave a Reply